Chengdu Daxinan Pharmaceutical Stock Co., Ltd

Established in Dec. 1998, Chengdu Daxinan Pharmaceutical Stock Co., Ltd is located in Jinniu district, Chengdu. It covers an area of 86,700m², with building area of 19,000m². In August 2000, the company reached quality management class A of Sichuan provincial pharmaceutical enterprises. In September of the same year, it passed national GMP Certification; the company bank credit grade is AAA.

Relying on the strong science and technology power and talented personnel advantage, the company is an prominent professional prescription drug company in domestic neuropsychiatric and digestant field, released the first SNRI antidepressant ‘Blossom’(venlafaxine hydrochloride capsule), the first antischizophrenic ‘Brisking’ (Aripiprazole tablet )in the world, and enteron motivator, new ‘Juyuansuan Moshabili Fensanpian’(Mosapride Citrate Dispersible Tablets). Among them, ‘Blossom’ was awarded ‘national class key new product’ in 1999, and acquired the small and medium technical enterprise science and technology creative fund. ‘Blossom’, ‘Juyuansuan Moshabili Fensanpian’(Mosapride Citrate Dispersible Tablets) and ‘Brisking’ are included in national torch plan projects. Daxinan Company imports advanced pharmaceutical equipment, owning advanced domestic slow-release tablet and dispersible tablets production technology, laid foundation for winning leading role in Chinese neuropsychiatric and digesting market. The company is armed with downstream product with independent intelligent property right and well effected prospecting market treatment, these will be put into market one after the other.

For five years, the company is consecutively keeping annual sales income increase rate above 50%, winning welcome from patients and gaining confidence of further development. The development of the company gets identification of society, listed Chengdu city’s 20 growing science and technology enterprises from 2001-2005 continuously for five years, having already been listed as 20 strong enterprises by Chengdu city government; the company becomes dominant tax payer of Jinniu district in Chengdu city.

    Under the concern and instruction from government of all levels, supporting strongly by patients and customers, the company is heading into prospecting future vigorously.